89 related articles for article (PubMed ID: 28720450)
1. Detection of cervical precancerous lesions with Aptima HPV assays using SurePath preservative fluid specimens.
Chernesky M; Jang D; Escott N; Gilchrist J; Li J; Elit L; Lytwyn A; Smieja M; Ratnam S; Arias M; Getman D; Weinbaum B; Kirkconnell B; Dockter J
Papillomavirus Res; 2017 Jun; 3():155-159. PubMed ID: 28720450
[TBL] [Abstract][Full Text] [Related]
2. Comparison of human papillomavirus detection by Aptima HPV and cobas HPV tests in a population of women referred for colposcopy following detection of atypical squamous cells of undetermined significance by Pap cytology.
Castle PE; Eaton B; Reid J; Getman D; Dockter J
J Clin Microbiol; 2015 Apr; 53(4):1277-81. PubMed ID: 25653409
[TBL] [Abstract][Full Text] [Related]
3. Aptima HPV Assay versus Hybrid Capture
Cook DA; Smith LW; Law J; Mei W; van Niekerk DJ; Ceballos K; Gondara L; Franco EL; Coldman AJ; Ogilvie GS; Jang D; Chernesky M; Krajden M
J Clin Virol; 2017 Feb; 87():23-29. PubMed ID: 27988420
[TBL] [Abstract][Full Text] [Related]
4. The reliability of high-risk human papillomavirus detection by Aptima HPV assay in women with ASC-US cytology.
Castle PE; Reid J; Dockter J; Getman D
J Clin Virol; 2015 Aug; 69():52-5. PubMed ID: 26209379
[TBL] [Abstract][Full Text] [Related]
5. Clinical Performance of SurePath™ Preservative Compared to PreservCyt® with Cobas® and Hybrid Capture® 2 HPV Tests in a Colposcopy Population.
Pyne MT; Tardif KD; Allen A; Sexsmith C; Lesher L; Adelman M; Janát-Amsbury MM; Schlaberg R
Clin Lab; 2019 Mar; 65(3):. PubMed ID: 30868858
[TBL] [Abstract][Full Text] [Related]
6. HPV genotyping and E6/E7 transcript assays for cervical lesion detection in an Asian screening population-Cobas and Aptima HPV tests.
Wong OGW; Tsun OKL; Tsui EY; Chow JNK; Ip PPC; Cheung ANY
J Clin Virol; 2018 Dec; 109():13-18. PubMed ID: 30368218
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of oncogenic human papillomavirus RNA and DNA tests with liquid-based cytology in primary cervical cancer screening: the FASE study.
Monsonego J; Hudgens MG; Zerat L; Zerat JC; Syrjänen K; Halfon P; Ruiz F; Smith JS
Int J Cancer; 2011 Aug; 129(3):691-701. PubMed ID: 20941740
[TBL] [Abstract][Full Text] [Related]
8. Cervical cancer screening cotesting with cytology and MRNA HPV E6/E7 yields high rates of CIN2+ lesions in young women.
Granados R; Tellez-Safina H; Solis I; Mateos F; Rodriguez-Barbero JM; Aramburu JA; Huertas MA; Bajo P; Camarmo E; Corrales T; Medina P; Calvo B; Martin E; Anta L; Zamora M; Alcaide T
Diagn Cytopathol; 2017 Dec; 45(12):1065-1072. PubMed ID: 28949442
[TBL] [Abstract][Full Text] [Related]
9. Clinical performance of the Cobas 4800 HPV test and the Aptima HPV assay in the management of women referred to colposcopy with minor cytological abnormalities.
Tewari P; White C; Kelly L; Pilkington L; Keegan H; D'Arcy T; Toole SO; Sharp L; O'Leary JJ; Martin CM
Diagn Cytopathol; 2018 Dec; 46(12):987-992. PubMed ID: 30284405
[TBL] [Abstract][Full Text] [Related]
10. Risk assessment and clinical impact of liquid-based cytology, oncogenic human papillomavirus (HPV) DNA and mRNA testing in primary cervical cancer screening (the FASE study).
Monsonego J; Hudgens MG; Zerat L; Zerat JC; Syrjänen K; Smith JS
Gynecol Oncol; 2012 Apr; 125(1):175-80. PubMed ID: 22233689
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of a new APTIMA specimen collection and transportation kit for high-risk human papillomavirus E6/E7 messenger RNA in cervical and vaginal samples.
Chernesky M; Jang D; Gilchrist J; Elit L; Lytwyn A; Smieja M; Dockter J; Getman D; Reid J; Hill C
Sex Transm Dis; 2014 Jun; 41(6):365-8. PubMed ID: 24825332
[TBL] [Abstract][Full Text] [Related]
12. Efficiency of the APTIMA HPV Assay for detection of HPV RNA and DNA targets.
Getman D; Aiyer A; Dockter J; Giachetti C; Zhang F; Ginocchio CC
J Clin Virol; 2009 Jul; 45 Suppl 1():S49-54. PubMed ID: 19651369
[TBL] [Abstract][Full Text] [Related]
13. High-risk HPV detection and genotyping by APTIMA HPV using cervical samples.
Pyne MT; Hamula CL; Tardif K; Law C; Schlaberg R
J Virol Methods; 2015 Sep; 221():95-9. PubMed ID: 25956671
[TBL] [Abstract][Full Text] [Related]
14. Aptima Human Papillomavirus E6/E7 mRNA Test Results Strongly Associated With Risk for High-Grade Cervical Lesions in Follow-Up Biopsies.
Ge Y; Christensen P; Luna E; Armylagos D; Xu J; Schwartz MR; Mody DR
J Low Genit Tract Dis; 2018 Jul; 22(3):195-200. PubMed ID: 29543688
[TBL] [Abstract][Full Text] [Related]
15. Comparative cost analysis of cervical cancer screening programme based on molecular detection of HPV in Spain.
Ibáñez R; Mareque M; Granados R; Andía D; García-Rojo M; Quílez JC; Oyagüez I
BMC Womens Health; 2021 Apr; 21(1):178. PubMed ID: 33902553
[TBL] [Abstract][Full Text] [Related]
16. A comparison of different human papillomavirus tests in PreservCyt versus SurePath in a referral population-PREDICTORS 4.
Cuzick J; Ahmad AS; Austin J; Cadman L; Ho L; Terry G; Kleeman M; Ashdown-Barr L; Lyons D; Stoler M; Szarewski A
J Clin Virol; 2016 Sep; 82():145-151. PubMed ID: 27498250
[TBL] [Abstract][Full Text] [Related]
17. Prevalence of Human Papillomavirus infection in unselected SurePath samples using the APTIMA HPV mRNA assay.
Rebolj M; Preisler S; Ejegod DM; Bonde J; Rygaard C; Lynge E
J Mol Diagn; 2013 Sep; 15(5):670-7. PubMed ID: 23827659
[TBL] [Abstract][Full Text] [Related]
18. Cervical Cytology Specimen Stability in Surepath Preservative and Analytical Sensitivity for HPV Testing with the cobas and Hybrid Capture 2 Tests.
Tardif KD; Pyne MT; Malmberg E; Lunt TC; Schlaberg R
PLoS One; 2016; 11(2):e0149611. PubMed ID: 26905067
[TBL] [Abstract][Full Text] [Related]
19. Development and Validation of a Preanalytic Procedure for Performing the cobas HPV Test in SurePath Preservative Fluid.
Krevolin MD; Hardy D; Pane J; Aslam S; Behrens CM
J Mol Diagn; 2017 Mar; 19(2):288-294. PubMed ID: 28041871
[TBL] [Abstract][Full Text] [Related]
20. Comparison of three human papillomavirus DNA assays and one mRNA assay in women with abnormal cytology.
Rebolj M; Lynge E; Ejegod D; Preisler S; Rygaard C; Bonde J
Gynecol Oncol; 2014 Dec; 135(3):474-80. PubMed ID: 25449563
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
